Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 8/24/2020 (updated 3/28/2024)
AgriSafe is a national non profit that offers occupational health and safety training for rural health professionals. Currently AgriSafe in partnership with Mississippi State University Extension and University of Mississippi Medical Center are offering Continuing Health Professional Education through four webinars listed below. One hour of continuing education is available for each webinar.
This continuing education opportunity is free to licensed health care providers in the state of Mississippi. For health care providers outside of Mississippi, the continuing education is available for $40 per CE hour.
Posted 4/20/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration-funded Opioid Response Network (ORN) initiative has launched the Stand Against Stigma (SAS) Challenge. This is an opportunity for those in the healthcare industry to address and dispel stigma related to individuals with substance use disorders through easy, daily activity.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.